OncoMed Pharmaceuticals Inc

OncoMed Pharmaceuticals — Merger or Acquisition (December 2018)

61 slides from OncoMed Pharmaceuticals's merger presentation, Dec 11, 2018

  1. Slide 1: Improving Outcomes for Patients in Rare Diseases

    Denise Scots - Knight – CEO Richard Jones – CFO Alastair Mackinnon - CMO December 2018 IMPROVING OUTCOMES FOR PATIENTS IN RARE DISEASES

  2. Slide 2: Disclaimer

    DISCLAIMER 1 Mereo BioPharma Group plc No Offer or Solicitation This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe f or or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any

  3. Slide 3: Forward Looking Statements

    FORWARD LOOKING STATEMENTS 2 Mereo BioPharma Group plc Forward - Looking Statements This communication contains “forward - looking statements”. All statements other than statements of historical fact contained in t his report are forward - looking statements within the meaning of Section 27A of the

  4. Slide 4: Combination of Mereo and OncoMed

    COMBINATION OF MEREO AND ONCOMED

  5. Slide 5: Key Transaction Terms

    KEY TRANSACTION TERMS 4 Upfront Stock Consideration • Issuance of new Mereo shares (in the form of newly registered ADRs) to OncoMed shareholders • Ownership split on completion 75% Mereo / 25% OncoMed shareholders (1) • Consideration represents a total value of $57 million and a 34% premium to Onco

  6. Slide 6: Strategic Rationale for the Combination

    STRATEGIC RATIONALE FOR THE COMBINATION 5 • Three phase 2 readouts in core orphan products in 2019 ( Mereo ’ s BPS - 804 and MPH - 966 ) • Potential partnerships of Mereo ’ s BCT - 197 and BGS - 649 programs • Potential partnership of OncoMed ’ s navicixizumab • Ongoing Celgene collaboration with an

  7. Slide 7: Management & Governance

    Dr. Peter Fellner Chairman Richard Jones Executive Director CFO MANAGEMENT & GOVERNANCE 6 John Richard Head of Corporate Development Richard Jones Chief Financial Officer Dr. Denise Scots - Knight Chief Executive Officer Wills Hughes - Wilson Head of Patient Access & Commercial Planning Charles Serm

  8. Slide 8: Next Steps

    NEXT STEPS 7 • Filing with the SEC of a Registration Statement on Form F - 4 for Mereo • Proxy statement of OncoMed (to be included in Mereo Form F - 4) • OncoMed shareholder meeting Targeting completion in H1 2019

  9. Slide 9: Overview of the Enlarged Mereo

    OVERVIEW OF THE ENLARGED MEREO

  10. Slide 10: Corporate and Commercial Strategy

    9 CORPORATE AND COMMERCIAL STRATEGY Bone/ Musculoskeletal Respiratory Endocrine BPS - 804 Setrusumab BGS - 649 * Leflutrozole MPH - 966 Alvelestat BCT - 197 * Acumapimod * Plan to partner for development and commercialization Potential new products Potential new products Key in House Expertise • Dev

  11. Slide 11: Mereo's Current Product Pipeline

    Mereo BioPharma Group plc 10 Product Candidate Indication Phase 1 Phase 2a Phase 2b Last Milestone Next Anticipated Milestones BPS - 804 (setrusumab) Osteogenesis Imperfecta Phase 2b initiated MPH - 966 (alvelestat) Severe Alpha - 1 Antitrypsin Deficiency Positive Phase2 data in bronchiectasis Phase

  12. Slide 12: Overview of OncoMed

    Mereo BioPharma Group plc 11 OVERVIEW OF ONCOMED OncoMed Overview • Clinical stage biopharmaceutical company focused on discovering and developing novel anti - cancer therapeutics • Headquartered in Redwood City, California • Currently has three therapeutic candidates in clinical development (Phase

  13. Slide 13: Mereo's Upcoming Key Milestones

    Mereo BioPharma Group plc 12 2018 2019 2020 2021 BPS - 804 MPH - 966 BGS - 649 BCT - 197 Additional Products MEREO’S UPCOMING KEY MILESTONES Pediatric Pivotal 12 month fracture Phase II Option : Commercial partnering Commercial partnering New product opportunities Adult HRPqCT data 6 m 12 m Extensio

  14. Slide 14: Combined Group Cash Runway Further Extended into 2020

    COMBINED GROUP CASH RUNWAY FURTHER EXTENDED INTO 2020 13 Key go forward funding priorities Mereo R&D spend on these programs $7.9m in in 1H18 Funding commitment ends in 2018 BCT - 197 Phase 2: Completed BGS - 649 Phase 2b: completes this year NAVI Phase 1B Etigilimab (anti - TIGIT) Phase 1A GITRL -

  15. Slide 15: BPS-804 Setrusumab (Acquired from Novartis in 2015)

    BPS - 804 SETRUSUMAB (ACQUIRED FROM NOVARTIS IN 2015)

  16. Slide 16: Osteogenesis Imperfecta: A Severe Genetic Bone Disease

    OSTEOGENESIS IMPERFECTA A SEVERE GENETIC BONE DISEASE 15 Mereo BioPharma Group plc

  17. Slide 17: Osteogenesis Imperfecta (OI)

    Mereo BioPharma Group plc OSTEOGENESIS IMPERFECTA (OI) 16 An orphan genetic chronic bone disorder characterised by fragile bones that break easily ̴ 6.2 OI cases per 100,000 population in the US 1 ̴ 10 OI cases per 100,000 population in the EU 2 Prevalence: 85% - 90% linked to a gene mutation that p

  18. Slide 18: OI Treatment: Drugs Used – None FDA or EMA Approved

    OI TREATMENT: DRUGS USED – NONE FDA OR EMA APPROVED FOR OI ▪ Bisphosphonates ▪ Alendronate, risedronate, pamidronate, zoledronate, etc. ▪ Approved for treatment of adult osteoporosis ▪ Synthetic analogues of pyrophosphate ▪ Inhibit bone resorption ▪ Can be given orally or intravenously, depending on

  19. Slide 19: BPS-804 Adult Phase 2b Study

    BPS - 804 ADULT PHASE 2B STUDY 18 Revised estimated enrolment: Trial arms: Study duration: 112 OI Patients Types I, III and IV 6 months open label data H1 2019 with 12 months H2 2019 Top line data from three blinded arms by the end of 2019 Three different monthly dosing regimens of BPS - 804 Open la

  20. Slide 20: BPS-804 Pediatric Phase 3 Study

    BPS - 804 – PEDIATRIC PHASE 3 STUDY 19 Estimated enrolment: 24 patients 5 - 18 years Total Study duration ~160 Severe OI Patients Types I, III and IV Initiation in 2019 first in EU and Canada Patients on bisphosphonate therapy One month dose finding – 3 doses versus placebo Additional 128 patients R

  21. Slide 21: Brittle Mouse Model – Treatment with BPS-804

    BRITTLE MOUSE MODEL – TREATMENT WITH BPS - 804 20 Mature Brtl control Mature Brtl treated Mature WT Control Mature WT Treated Mereo Biopharma Group plc

  22. Slide 22: The OFELY Study and HRpQCT

    THE OFLEY STUDY AND HRPQCT 21 Bone Microarchitecture Assessed by HR - pQCT as Predictor of Fracture Risk in Postmenopausal Women Sornay - Rendu et al JBMR March 09 2017 • Prospective study investigating the prediction of fracture ( Fx ) by bone microarchitecture assessed by HR - pQCT in postmenopaus

  23. Slide 23: HRpQCT Scans of Patients with OI and Controls

    HRPQCT SCANS OF PATIENTS WITH OI AND CONTROLS 22 Mereo Biopharma Group plc

  24. Slide 24: BPS-804 Regulatory Update

    BPS - 804 REGULATORY UPDATE 23 Orphan drug status EU and US PIP agreed with EMA Admitted to the Adaptive Pathway and PRIME in the EU • Ongoing interactive dialogue with EMA and HTA’s • Real world evidence/registries Plan to engage with the FDA on extending the pediatric Phase 3 trial to sites in the

  25. Slide 25: MPH-966 (formerly AZD-9668) Alvelestat (Acquired from AstraZeneca in 2017)

    MPH - 966 (formerly AZD - 9668) ALVELESTAT (ACQUIRED FROM ASTRA ZENECA IN 2017)

  26. Slide 26: Alpha-1 Antitrypsin Deficiency (AATD)

    Mereo BioPharma Group plc ALPHA - 1 ANTITRYPSIN DEFICIENCY (AATD) An orphan genetic disorder that results in pulmonary disease North America ~ 50,000 Europe ~60,000 Estimated prevalence of target patients ( PiZZ and Nulls) Symptoms: • Age 20 - 50 - wheeze and reduced exercise tolerance • PiZZ and Nu

  27. Slide 27: Restoring the Balance in Alpha-1 Lung Disease with Alvelestat

    Mereo BioPharma Group plc RESTORING THE BALANCE IN ALPHA - 1 LUNG DISEASE WITH NEUTROPHIL ELASTASE INHIBITOR - ALVELESTAT 26 Elastase Anti - Elastase Alpha - 1 antitrypsin Alvelestat

  28. Slide 28: CT Images Showing the Lung of an AATD Patient

    CT IMAGES SHOWING THE LUNG OF AN ALPHA - 1 ANTITRYPSIN DEFICIENT PATIENT 15 Normal lung AATD lung Mereo Biopharma Group plc

  29. Slide 29: MPH-966 – Relevant Clinical Studies To-Date

    MPH - 966 – RELEVANT CLINICAL STUDIES TO - DATE Cystic Fibrosis • Total of 56 patients in one study • 27 patients treated for 4 weeks with 60mg BD • Statistically significant reduction in the biomarker urine desmosine Bronchiectasis • Total of 38 patients in one study • 22 patients treated for 4 wee

  30. Slide 30: MPH-966 – Proof of Concept Phase 2 Study

    MPH - 966 – PROOF OF CONCEPT PHASE 2 STUDY • Three - arm study with two different dosing arms versus placebo • Planned enrollment - 165 patients completed • Treatment duration - 12 weeks • FPI in November 2018 Primary Endpoint • Desmosine - biomarker shown to have correlation with lung density by CT

  31. Slide 31: BCT-197 Acumapimod (Acquired from Novartis in 2015)

    BCT - 197 ACUMAPIMOD (ACQUIRED FROM NOVARTIS IN 2015)

  32. Slide 32: Acute Exacerbations of COPD (AECOPD)

    Mereo BioPharma Group plc ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AE COPD) 31 16m COPD cases diagnosed in the US 1 13m COPD cases estimated in the EU 2 Prevalence: >1.5m Hospital visits per year 3 COPD includes chronic bronchitis, emphysema and some forms of bronchiectasis Symp

  33. Slide 33: BCT-197 Met the Primary Endpoint in the Phase 2 Trial

    32 PRIMARY ENDPOINT (CHANGE IN FEV1 FROM BASELINE TO DAY 7 WITHIN THE TREATMENT GROUP) Primary endpoint met on an ITT basis for both high and low dose regimens (p= 0.012, p ≤ 0.001) versus no significant change from baseline (p=0.102) for Standard of Care plus placebo POSITIVE CLINICAL AND HEALTH EC

  34. Slide 34: BCT-197 Reduced Inflammatory Markers hsCRP and Fibrinogen

    BCT - 197 RESULTED IN A SIGNIFICANT REDUCTION IN THE INFLAMMATORY MARKERS HSCRP AND FIBRINOGEN IN THE FIRST 14 DAYS DURING THE INDEX EXACERBATIO N 33 • Dose – dependent, statistically significant reductions in key inflammatory markers hsCRP and fibrinogen • Suppression of hsCRP maintained through th

  35. Slide 35: BGS-649 Leflutrozole (Acquired from Novartis in 2015)

    BGS - 649 LEFLUTROZOLE (ACQUIRED FROM NOVARTIS IN 2015)

  36. Slide 36: Hypogonadotropic Hypogonadism (HH) in Obese Men

    HYPOGONADOTROPIC HYPOGONADISM (HH) IN OBESE MEN 35 A highly prevalent clinical syndrome that results from inadequate levels of testosterone ̴ 35.5 % Adult males in the US are obese 1 ̴ 21.9 % Adult males in the EU are obese 1 Prevalence: ̴ 15.8 % HH prevalence in obese men 2 12 million* obese men wi

  37. Slide 37: Hypogonadotropic Hypogonadism – Treatment Landscape

    HYPOGONADOTROPIC HYPOGONADISM – TREATMENT LANDSCAPE 36 TOPICAL TESTOSTERONE Black box warning – secondary exposure to testosterone Suppression of LH and FSH (loss of fertility) Potential for supra physiological levels of testosterone – cardiovascular Daily application – messy to apply Mereo BioPharm

  38. Slide 38: BGS-649 Met the Primary Endpoint in the Phase 2b Trial

    BGS - 649 MET THE PRIMARY END POINT IN THE PHASE 2B TRIAL TOTAL OF 271 PATIENTS 37 • PRIMARY ENDPOINT : normalisation of testosterone @ 24 wk in > 75 % subjects ‒ Met at all three doses p< 0.001 versus placebo ‒ No patient > 1500 ng/dl at any time point, in the treatment groups • SECONDARY ENDPOINT

  39. Slide 39: BGS-649 Met the Secondary Endpoints in the Phase 2b Trial

    38 BGS - 649 MET THE SECONDARY END POINTS IN THE PHASE 2B TRIAL Total of 271 patients LS Mean change from baseline in FSH in ITT population (MMRM) LS Mean change from baseline in LH in ITT population (MMRM) SECONDARY ENDPOINTS Change in fertility hormones (LH and FSH) from baseline at 24 weeks met a

  40. Slide 40: 1H 2018 Mereo Financial Results

    1H 2018 MEREO FINANCIAL RESULTS

  41. Slide 41: Financial Highlights

    FINANCIAL HIGHLIGHTS 40 Mereo BioPharma Group plc £126 million* R&D spend in 1H 2018 £ 10.9 million Cash and short term deposits and short term investments at June 30 2018: £36.9 million* £ 7.1 million Funded through to key clinical milestones *(gross including debt facility ) (£3.8m on non - GAAP a

  42. Slide 42: Appendix

    APPENDIX

  43. Slide 43: Robust Intellectual Property Portfolio

    ROBUST INTELLECTUAL PROPERTY PORTFOLIO 2017 2019 2021 2023 2025 2027 2029 2031 2033 2035 2037 Compound per se – granted in all major territories Data/Marketing Exclusivity depending on MA date SPC/Term Extension Compound per se – granted in all major territories BCT - 197 MPH - 966 BPS - 804 Antibod

  44. Slide 44: Transaction Mereo and NVS/AZ Entitlement

    43 Transaction Mereo Entitlement NVS/AZ Entitlement Licence of product in territory or worldwide Majority percent of licensing income (upfront, milestones and royalties) Share of licensing income (upfront, milestones and royalties) Commercialisation by Mereo (territory or worldwide) Product sales As

  45. Slide 45: Robust Product Candidate Selection Criteria

    Clinically meaningful data Clear clinical & regulatory strategy Clinical trials to reach value creating milestone Optionality around further value creation Indication with unmet medical need Sourced from large pharma companies Scientific rationale & robust data package Favourable competitive landsca

  46. Slide 46: BPS-804 (OI) Completed Clinical Studies

    Mereo BioPharma Group plc BPS - 804 (OI) 45 Completed clinical studies to date: • 83 patients have received BPS - 804 • Statistically significant improvement in BMD and bone biomarkers in OI patients (P1NP, P1CP, BSAP and OC) • Down regulation of bone resorption biomarker CTX - 1 in OI patients • We

  47. Slide 47: Range of Severity in OI

    RANGE OF SEVERITY IN OI ‘Quantitative collagen Qualitative collagen defects defects Les vere Moderate | Lethal Common Non-deforming | Progressively Perinatally variable with with blue sclera | deforming | vatiable with | jethat Gene Protein Inheritance Type! Type Ill Type IV Type Il “20% of O1 Colla

  48. Slide 48: Non-Pharmacological Treatments

    NON - PHARMACOLOGICAL TREATMENTS • Metal rod insertion (not plates!) into long bones (since 1940s) 47 • Spinal fusion for scoliosis • Physiotherapy to strenghten muscles, improve motility • Physical aids (crutches, wheelchairs, splints, … ) • Community support

  49. Slide 49: Setrusumab: Mechanism of Action

    48 SETRUSUMAB: MECHANISM OF ACTION • In the absence of sclerostin, Wnt activates Dishevelled through LRP 5/6/Frizzled • The intracellular pathways upregulate target gene expression, osteoblast differentiation, proliferation & survival, leading to increased bone formation • Sclerostin (secreted by os

  50. Slide 50: BPS-804: Statistical Significant Benefit for Markers of Bone Mineralization

    Mereo BioPharma Group plc 49 49 BPS - 804: Statistical significant benefit for markers of bone mineralization * Statistical significance Day 43 BPS - 804 Reference Parameter N Geometric mean to baseline P value N Geometric mean to baseline P value PINP 9 1.84 <0.001* 5 1.06 0.651 PICP 9 1.53 0.003*

  51. Slide 51: BPS-804 (OI) – Historic Data

    Mereo BioPharma Group plc BPS - 804 (OI) - HISTORIC DATA 50 Completed clinical studies to date: • 83 patients have received BPS - 804 • Statistically significant improvement in BMD and bone biomarkers in OI patients (P1NP, P1CP, BSAP and OC) • Down regulation of bone resorption biomarker CTX - 1 in

  52. Slide 52: Alpha Antitrypsin Deficiency Current Treatment

    ALPHA 1 ANTITRYPSIN DEFICIENCY CURRENT TREATMENT • Routine COPD medications • Augmentation therapy: - Plasma derived alpha 1 anti trypsin - Weekly one hour IV infusion - Approval based on restoration of A1AT to a threshold level NOT clinical outcome data - Cost $150k pa - ~9,000 patients treated • S

  53. Slide 53: Long Term Augmentation and Short Term Treatment with AZD-9668 – Impact on Desmosine

    LONG TERM AUGMENTATION AND SHORT TERM TREATMENT WITH AZD - 9668 – IMPACT ON DESMOSINE RAPID study - 2 years of augmentation in AATD patients • Reduced loss of lung density: - Total lung capacity (TLC) - 1.45g/l/year vs - 2.19 g/l/year (P=0.03) • Post hoc analysis demonstrated correlation in change i

  54. Slide 54: BCT197 Reduced Subsequent Exacerbation in Frequent Exacerbators

    BCT197 REDUCED THE PERCENTAGE OF PATIENTS WHO SUFFERED A SUBSEQU ENT EXACERBATION IN FREQUENT EXACERBATORS 53 • Effect on moderate/severe exacerbations best seen in patients with >= 2 exacerbations / year • Patient population with highest unmet need Mereo Biopharma Group plc 47% 40% 25% 53% 60% 75 %

  55. Slide 55: BCT-197: Improvement in FEV1

    BCT - 197: IMPROVEMENT IN FEV1 54 Completed clinical studies to date: • 310 subjects have received BCT - 197 • Dosed at 75mg x 2 – AUC over exacerbation period (14 days) shows a statistically significant improvement in FEV1 vs placebo and prednisolone (P=0.0198 and 0.0102) • Well tolerated in the ta

  56. Slide 56: BGS-649 (HH): HPT Feedback Loop Process

    Mereo BioPharma Group plc BGS - 649 (HH): HPT FEEDBACK LOOP PROCESS 55

  57. Slide 57: H1 2018 Financial Results

    H1 2018 FINANCIAL RESULTS

  58. Slide 58: Summary of Financial Results for the Six Months Ended June 30 2018

    57 Mereo BioPharma Group plc SUMMARY OF FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE, 30 2018 H1’18 H1’18 £’000 Share based payments £’000 Fx £’000 One off legal costs £’000 H1’2018 Non - GAAP £’000 H1’2017 Non - GAAP £’000 Development costs (10,864) 337 - (10,527) (20,823) Admin expenses (7,102)

  59. Slide 59: R&D Costs by Segment

    0 1 2 3 4 5 6 7 8 9 BPS-804 MPH-966 BGS-649 BCT-197 R&D personnel H1’17 vs H1 ‘18 H1'17 H1'18 58 R&D COSTS BY SEGMENT (£’M) Total R&D costs H1 ‘18 £10.9m (H1’17: £21.4m) Mereo BioPharma Group plc

  60. Slide 60: Total Operating Costs by Segment

    0 2 4 6 8 10 12 14 16 BPS-804 AZD-9668 BGS-649 BCT-197 G&A 2015 to 2017 2015 2016 2017 59 TOTAL OPERATING COSTS BY SEGMENT (£’M) Total spend (operating loss) in 2017 £45.3m Mereo BioPharma Group plc

  61. Slide 61: Contact: One Cavendish Place, London

    Mereo BioPharma Group plc One Cavendish Place London, W1G 0QF UK +44 (0)333 0237 300

OncoMed Pharmaceuticals — Merger or Acquisition (December 2018) on 6ix